Evoke Pharma, Inc.
EVOK · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $4,284 | $3,752 | $3,080 | $3,308 |
| % Growth | 14.2% | 21.8% | -6.9% | – |
| Cost of Goods Sold | $102 | $168 | $42 | $119 |
| Gross Profit | $4,182 | $3,584 | $3,039 | $3,190 |
| % Margin | 97.6% | 95.5% | 98.6% | 96.4% |
| R&D Expenses | $5 | $8 | $43 | $16,321,984 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $5,314 | $5,135 | $4,298 | $4,384 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$16,321,984 |
| Operating Expenses | $5,320 | $5,143 | $4,340 | $4,384 |
| Operating Income | -$1,138 | -$1,559 | -$1,302 | -$1,194 |
| % Margin | -26.6% | -41.5% | -42.3% | -36.1% |
| Other Income/Exp. Net | -$19 | -$12 | -$4 | $1 |
| Pre-Tax Income | -$1,156 | -$1,571 | -$1,306 | -$1,193 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1,156 | -$1,571 | -$1,306 | -$1,193 |
| % Margin | -27% | -41.9% | -42.4% | -36.1% |
| EPS | -0.45 | -0.62 | -0.51 | -0.8 |
| % Growth | 27.4% | -21.6% | 36.3% | – |
| EPS Diluted | -0.45 | -0.62 | -0.51 | -0.8 |
| Weighted Avg Shares Out | 2,557 | 2,553 | 2,549 | 1,486 |
| Weighted Avg Shares Out Dil | 2,557 | 2,553 | 2,549 | 1,486 |
| Supplemental Information | – | – | – | – |
| Interest Income | $108 | $113 | $119 | $127 |
| Interest Expense | $126 | $125 | $123 | $126 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$1,030 | -$1,446 | -$1,183 | -$1,067 |
| % Margin | -24% | -38.5% | -38.4% | -32.2% |